Liquid biopsy has transformed how we think about cancer detection, prenatal testing, and transplant monitoring. But behind every liquid biopsy result is a step that rarely gets talked about: the extraction of circulating cell-free DNA (cfDNA) from plasma. For decades, that step has been handled by silica membrane columns and magnetic bead systems, and while these methods work, they come with real limitations. They are slow, they rely on harsh chemical conditions, and they can struggle to capture the short, fragile DNA fragments that make cfDNA analysis possible in the first place.
BioEcho has been working on a different approach, and a new study published in Scientific Reports offers some compelling early evidence that it is worth paying attention to.
The paper, authored by researchers from Karlsruhe Institute of Technology in collaboration with BioEcho scientists Benedikt Buerfent and Timo Hess, presents a proof of concept for Aqueous Two-Phase System (ATPS)-based cfDNA extraction. Rather than forcing DNA to bind to a solid surface and then releasing it through sequential washes, ATPS works through liquid-liquid partitioning. Short DNA fragments selectively migrate into a salt-rich bottom phase while an impressive 99.7% of plasma proteins are removed into the upper phase. A reverse elution step then purifies and concentrates the DNA up to fourfold, all under mild aqueous conditions with no lysis required in many cases and no toxic reagents involved.
The underlying principle will feel familiar to anyone who knows BioEcho's EchoLUTION platform. Both approaches share the same core philosophy: remove the unnecessary complexity that conventional purification methods have built up over decades, and let the biology do more of the work. Where EchoLUTION uses a flow-through matrix to purify nucleic acids in a single step, ATPS achieves separation through the physics of phase partitioning. Different mechanisms, same commitment to simplicity and sample integrity.
The practical results from the study are encouraging. The ATPS workflow delivers a roughly 10-minute turnaround, around six times faster than the conventional silica-based extraction methods used as the benchmark, with only about 2 minutes of hands-on time. DNA recovery was consistently above 60% even at low input concentrations, and the size profile of extracted DNA showed a natural cutoff around 750 bp, meaning the method selectively enriches the short fragments that matter most for sensitive diagnostics while leaving behind larger contaminating genomic DNA. Importantly, the extracts showed no PCR inhibition and were fully compatible with NGS library preparation, with defined variants successfully detected at 5% variant allele frequency.
There are honest trade-offs to acknowledge. Total DNA yield is somewhat lower than the silica-based reference method, and the work so far has been carried out with reference material spiked into healthy donor plasma rather than real patient samples. Validation with clinical specimens will be needed before this moves into diagnostic settings. But as a proof of concept, it is a genuinely interesting result, and the potential advantages in cost, throughput, and scalability are real.
For BioEcho, this publication reflects a broader research direction: rethinking the fundamentals of nucleic acid extraction rather than optimizing around existing constraints. The company's EchoLUTION technology already demonstrates what is possible when you step away from the bind-wash-elute paradigm. This ATPS work suggests that the same thinking can be applied to some of the most demanding sample types in molecular diagnostics.
The full study is available open access in Scientific Reports: https://www.nature.com/articles/s41598-026-45585-z
To learn more about BioEcho's nucleic acid purification technologies, visit www.bioecho.com.
BioEcho has been working on a different approach, and a new study published in Scientific Reports offers some compelling early evidence that it is worth paying attention to.
The paper, authored by researchers from Karlsruhe Institute of Technology in collaboration with BioEcho scientists Benedikt Buerfent and Timo Hess, presents a proof of concept for Aqueous Two-Phase System (ATPS)-based cfDNA extraction. Rather than forcing DNA to bind to a solid surface and then releasing it through sequential washes, ATPS works through liquid-liquid partitioning. Short DNA fragments selectively migrate into a salt-rich bottom phase while an impressive 99.7% of plasma proteins are removed into the upper phase. A reverse elution step then purifies and concentrates the DNA up to fourfold, all under mild aqueous conditions with no lysis required in many cases and no toxic reagents involved.
The underlying principle will feel familiar to anyone who knows BioEcho's EchoLUTION platform. Both approaches share the same core philosophy: remove the unnecessary complexity that conventional purification methods have built up over decades, and let the biology do more of the work. Where EchoLUTION uses a flow-through matrix to purify nucleic acids in a single step, ATPS achieves separation through the physics of phase partitioning. Different mechanisms, same commitment to simplicity and sample integrity.
The practical results from the study are encouraging. The ATPS workflow delivers a roughly 10-minute turnaround, around six times faster than the conventional silica-based extraction methods used as the benchmark, with only about 2 minutes of hands-on time. DNA recovery was consistently above 60% even at low input concentrations, and the size profile of extracted DNA showed a natural cutoff around 750 bp, meaning the method selectively enriches the short fragments that matter most for sensitive diagnostics while leaving behind larger contaminating genomic DNA. Importantly, the extracts showed no PCR inhibition and were fully compatible with NGS library preparation, with defined variants successfully detected at 5% variant allele frequency.
There are honest trade-offs to acknowledge. Total DNA yield is somewhat lower than the silica-based reference method, and the work so far has been carried out with reference material spiked into healthy donor plasma rather than real patient samples. Validation with clinical specimens will be needed before this moves into diagnostic settings. But as a proof of concept, it is a genuinely interesting result, and the potential advantages in cost, throughput, and scalability are real.
For BioEcho, this publication reflects a broader research direction: rethinking the fundamentals of nucleic acid extraction rather than optimizing around existing constraints. The company's EchoLUTION technology already demonstrates what is possible when you step away from the bind-wash-elute paradigm. This ATPS work suggests that the same thinking can be applied to some of the most demanding sample types in molecular diagnostics.
The full study is available open access in Scientific Reports: https://www.nature.com/articles/s41598-026-45585-z
To learn more about BioEcho's nucleic acid purification technologies, visit www.bioecho.com.
